A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding
Autor: | Yingyi Long, Wang Wang, Aishun Jin, Chao Hu, Shuyi Song, Huajun Zhang, Xiaojian Han, Shenglong Li, Bo Zhang, Feiyang Luo, Yingming Wang, Tingting Li |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.drug_class
viruses Biophysics In Vitro Techniques Monoclonal antibody Antibodies Viral Biochemistry Giant Cells Virus Article Syncytia Receptor binding motif Protein Domains Viral entry Antibody Specificity medicine Humans S1 shedding Viral shedding Neutralizing antibody Molecular Biology COVID-19 Serotherapy Binding Sites biology SARS-CoV-2 HEK 293 cells Immunization Passive COVID-19 Antibodies Monoclonal Cell Biology Virology Antibodies Neutralizing Virus Shedding Protein Subunits HEK293 Cells Monoclonal Spike Glycoprotein Coronavirus biology.protein Antibody |
Zdroj: | Biochemical and Biophysical Research Communications |
ISSN: | 1090-2104 0006-291X |
Popis: | Potent neutralizing antibodies (Abs) have been proven with therapeutic efficacy for the intervention against SARS-CoV-2. Majority of these Abs function by directly interfering with the virus entry to host cells. Here, we identified a receptor binding domain (RBD) specific monoclonal Ab (mAb) 82A6 with efficient neutralizing potency against authentic SARS-CoV-2 virus. As most Abs targeting the non-receptor binding motif (RBM) region, 82A6 was incapable to block the RBD-ACE2 interaction. In particular, it actively promoted the S1 subunit shedding from the S protein, which may lead to effective reduction of intact SARS-CoV-2 viruses. Importantly, it could block potential syncytia formation associated with post-infectious cell surface expression of S proteins. Our study evidenced a RBD specific Ab with unique beneficial efficacy against SARS-CoV-2 infection, which might bring informative significance to understand the collective effects of neutralizing Abs elicited in COVID-19 patients. |
Databáze: | OpenAIRE |
Externí odkaz: |